Opendata, web and dolomites

Cluster-Buster SIGNED

Development of small molecule inhibitors of circulating tumor cell clusters

Total Cost €


EC-Contrib. €






Project "Cluster-Buster" data sheet

The following table provides information about the project.


Organization address
address: PETERSPLATZ 1
city: BASEL
postcode: 4051

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-PoC
 Funding Scheme ERC-POC
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2020-10-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITAT BASEL CH (BASEL) coordinator 150˙000.00


 Project objective

Despite the great progress that has been made in treating cancer, metastasis remains incurable. Metastasis accounts for 8 million deaths per year worldwide and no agents are currently available to prevent the metastatic spread of cancer. The metastatic process begins with cancer cells leaving the primary tumor site and entering the blood circulation. In circulation, cancer cells are defined as circulating tumor cells (CTCs), and are typically found in the form of single CTCs or small CTC aggregates (CTC clusters). Upon dissemination and survival into distant organs, cancer cells give rise to proliferating metastatic lesions, which in turn can shed other CTCs and form additional metastases. While virtually all oncology-related drugs aim to kill cancer cells within a tumor, no drugs are available to target metastatic cells in circulation. As a consequence, no drugs are available to block or prevent the metastatic cascade. We recently discovered that CTC clusters are exceptionally efficient metastatic precursors, capable to initiate a metastasis 50-times better than single CTCs. Within our ERC Starting Grant Project Holding-Hands, through a screen with 2’456 FDA-approved compounds, we discovered those that enable the disaggregation of CTC clusters in breast cancer mouse models and consequently, lead to metastasis suppression. This exciting new discovery implies that targeting CTC clusters is now feasible, and that this approach is likely to delay or prevent metastasis formation in cancer patients. Thus, within this Proof of Concept application, we aim to screen and patent additional cluster-targeting compounds with higher efficacy and better safety profile, to establish a new company whose aim is to commercialize cluster-targeting molecules, and to prepare for clinical trials.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CLUSTER-BUSTER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CLUSTER-BUSTER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

NanoPD_P (2020)

High throughput multiplexed trace-analyte screening for diagnostics applications

Read More  


Dynamic Modeling of Labor Market Mobility and Human Capital Accumulation

Read More  

TALNET (2020)

Transparent Aluminium Networks

Read More